315 results
Page 9 of 16
8-K
EX-99.1
k72g72dbbng5vbolvkp
9 Feb 11
Other Events
12:00am
8-K
EX-99.1
8aaj8 anf09gp87ldixk
2 Feb 11
Discovery Labs Provides Expanded Update Regarding its Program for Surfaxin® U.S. Marketing Authorization
12:00am
CORRESP
ykhy17n
10 Nov 10
Correspondence with SEC
12:00am
8-K
EX-99.1
gtlo6ncw9f9p xs5ye
9 Nov 10
Results of Operations and Financial Condition
12:00am
CORRESP
8ef82r592lw36utjj8
8 Nov 10
Correspondence with SEC
12:00am
8-K
EX-99.1
d9wz0x
4 Nov 10
Other Events
12:00am
424B5
8q59jn4oztcjvjyc
13 Oct 10
Prospectus supplement for primary offering
12:00am
8-K
EX-99.1
9elt502pflp17
13 Oct 10
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
hpsycq j9cfd
4 Aug 10
Discovery Labs Provides Business Update and Reports Second Quarter 2010 Financial Results
12:00am
424B5
a0ynq 1d6u0kig7p20ke
18 Jun 10
Prospectus supplement for primary offering
12:00am
8-K
EX-1.1
dvp79kxkt3 g4
17 Jun 10
Discovery Labs Prices $10.0 Million Public Offering of
12:00am
424B5
wru4nj 8ap
16 Jun 10
Prospectus supplement for primary offering
12:00am
424B3
vqu63a1s3q5i6mjdts5t
15 Jun 10
Prospectus supplement
12:00am
8-K
EX-99.1
2qqftcgvd
9 Jun 10
Discovery Labs Receives FDA Guidance Regarding Preclinical Program to
12:00am
8-K
EX-99.1
gp2v59v0
9 Jun 10
Discovery Labs Reports Preliminary Results from Phase 2 Clinical Trial of Surfaxin in Pediatric Acute Respiratory Failure
12:00am
8-K
qoohk23
21 May 10
Discovery Labs Achieves Key Milestone Towards Potential Surfaxin® Approval
12:00am
8-K
EX-99.1
vqtmrl78uqx8
21 May 10
Discovery Labs Achieves Key Milestone Towards Potential Surfaxin® Approval
12:00am